Crescent Biopharma (CBIO) Partnership summary

Opening remarks and agenda

• Conference call and webcast held to announce a transformational partnership with Kelun-Biotech and provide pipeline updates, with leadership team introduced.

• Forward-looking statements and safe harbor provisions noted.

Objectives of the partnership

• Partnership aims to accelerate and expand leadership in immuno-oncology (IO) and ADC combination therapies, advancing next-generation solid tumor therapeutics.

• Collaboration enables parallel clinical data generation in the US, Europe, and Greater China.

• Both parties will co-develop CR-001 and CR-003 (SKB105), focusing on global and regional clinical advancement.

Partner introductions and roles

• Crescent advances CR-001 in the US and Europe, while Kelun-Biotech leads in Greater China.

• Kelun-Biotech brings end-to-end ADC development capabilities and access to Chinese markets.

• Both companies share clinical data and can independently develop CR-001 in additional combinations.